These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 19224856

  • 1. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
    Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM.
    J Clin Oncol; 2009 Mar 20; 27(9):1382-7. PubMed ID: 19224856
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
    Lane HA, Lebwohl D.
    Semin Oncol; 2006 Apr 20; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
    [Abstract] [Full Text] [Related]

  • 4. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
    Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G.
    Breast Cancer Res Treat; 2010 Jun 20; 121(2):399-411. PubMed ID: 20428938
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.
    Kendall A, Anderson H, Dunbier AK, Mackay A, Dexter T, Urruticoechea A, Harper-Wynne C, Dowsett M.
    Cancer Epidemiol Biomarkers Prev; 2008 Apr 20; 17(4):855-63. PubMed ID: 18398027
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM.
    Adv Ther; 2008 Dec 20; 25(12):1257-75. PubMed ID: 19096768
    [Abstract] [Full Text] [Related]

  • 9. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
    Acta Oncol; 2009 Dec 20; 48(4):522-31. PubMed ID: 19173092
    [Abstract] [Full Text] [Related]

  • 10. Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
    Bhatnagar AS.
    Breast; 2006 Feb 20; 15 Suppl 1():S3-13. PubMed ID: 16500235
    [Abstract] [Full Text] [Related]

  • 11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
    J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
    Bedard PL, Singhal SK, Ignatiadis M, Bradbury I, Haibe-Kains B, Desmedt C, Loi S, Evans DB, Michiels S, Dixon JM, Miller WR, Piccart MJ, Sotiriou C.
    Endocr Relat Cancer; 2011 Dec 01; 18(6):721-30. PubMed ID: 21984694
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors.
    Miller WR, Larionov A, Anderson TJ, Walker JR, Krause A, Evans DB, Dixon JM.
    Cancer; 2008 Feb 01; 112(3 Suppl):689-694. PubMed ID: 18072233
    [Abstract] [Full Text] [Related]

  • 17. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
    Miller WR, Larionov A.
    Breast Cancer Res; 2010 Feb 01; 12(4):R52. PubMed ID: 20646288
    [Abstract] [Full Text] [Related]

  • 18. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
    Salmon RJ, Alran S, Malka I, de Cremoux P, Rosty C, Languille O, Campana F, Breast Group of the Institut Curie, Sigal-Zafrani B.
    Am J Clin Oncol; 2006 Aug 01; 29(4):385-8. PubMed ID: 16891867
    [Abstract] [Full Text] [Related]

  • 19. Letrozole.
    Dellapasqua S, Colleoni M.
    Expert Opin Drug Metab Toxicol; 2010 Feb 01; 6(2):251-9. PubMed ID: 20095792
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
    Chow LW, Yip AY, Loo WT, Toi M.
    Cancer Lett; 2008 Apr 18; 262(2):232-8. PubMed ID: 18248884
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.